Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis: Gabapentin and pregabalin in treating fibromyalgia
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
WHAT IS KNOWN AND OBJECTIVES: Fibromyalgia (FBM) is a common chronic pain disorder affecting up to 2% of the general population. Current treatment options are mostly symptom-based and limited both in efficacy and number. Two promising alternatives are gabapentin (GP) and pregabalin (PB). We aimed to estimate the efficacy and safety/tolerability of the two compounds in FBM through a systematic review and a meta-analysis of relevant randomized double-blind placebo-controlled (RCT) were performed. DATA SOURCES, EXTRACTION AND ANALYSIS: A literature search was conducted through MEDLINE, EMBASE, Cochrane CENTRAL and the reference lists of relevant studies. Responders to treatment (>30% reduction in mean pain score) and dropouts due to lack of efficacy were used as primary outcome measures. Dropout rates and incidence of common adverse outcomes were also investigated. Four RCTs, reporting data on 2040 patients, were reviewed and three of them using PG were included in the meta-analysis. RESULTS: Pregabalin at a dose of 600, 450 and 300 mg per day is effective in FBM compared to placebo (NNT: 7, upper 95% CI: 12, 450 mg). A number of adverse events (AE), such as dizziness, somnolence, dry mouth, weight gain, peripheral oedema, is consistently associated with treatment at any dose and could lead one out of four patients to quit treatment (NNH: 6, lower 95% CI: 4, 600 mg). Indirect comparison meta-analysis suggests that PB at a dose of 450 mg per day could result in more responders than at 300 mg, but this result needs to be interpreted with caution as there were no significant differences between 600 and 300 mg or between 600 and 450 mg. Data on GP is limited. WHAT IS NEW AND CONCLUSIONS: The analysis indicates that PB at a dose of 450 mg per day is most likely effective in treating FBM, although AE are not negligible. Further evidence is necessary for more conclusive inferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206 · cited 1×
“Network meta-analysis techniques are useful for assessing the relative effectiveness of two treatments when they have not been compared directly in a randomized trial but have each been compared to a common comparator (50, 51).”
MethodAn internet survey of 2,596 people with fibromyalgia
Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J., & Matallana, L. (2007) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-8-27 · Cited by 865 · cited 1×
“Recently, it has been suggested that poor sleep is a key symptom of FBM (57).”
BackgroundManagement of fibromyalgia syndrome
Goldenberg, D. L. (2004) · JAMA · doi:10.1001/jama.292.19.2388 · Cited by 850
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
Carville, S. F., Arendt-Nielsen, S., Bliddal, H., Blotman, F., Branco, J. C., Buskila, D., Da Silva, J. A. P., Danneskiold-Samsøe, B., Dincer, F., Henriksson, C., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071522 · Cited by 752
Elevated cerebrospinal fluid levels of substance p in patients with the fibromyalgia syndrome
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., Lopez, Y., & Mackillip, F. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371106 · Cited by 679
Treatment of fibromyalgia with antidepressants: A meta-analysis
O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.06279.x · Cited by 340
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
A Double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia
Wolfe, F., Cathey, M. A., & Hawley, D. J. (1994) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749409103725 · Cited by 252
Simpson's paradox and calculation of number needed to treat from meta-analysis
Cates, C. J. (2002) · BMC Medical Research Methodology · doi:10.1186/1471-2288-2-1 · Cited by 251
Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236 · cited 2×
“One was a study investigating the durability of efficacy of PB in treating FBM, after efficacy was established in an open label treatment phase (52).”
Background
Cited by
Fibromyalgia: A Clinical Review
Clauw, D. J. (2014) · JAMA · doi:10.1001/jama.2014.3266 · Cited by 1,674
EULAR revised recommendations for the management of fibromyalgia
Macfarlane, G. J., Kronisch, C., Dean, L. E., Atzeni, F., Häuser, W., Fluß, E., Choy, E., Kosek, E., Amris, K., Branco, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209724 · Cited by 1,566
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment
Sarzi-Puttini, P., Giorgi, V., Marotto, D., & Atzeni, F. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-00506-w · Cited by 793
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 690
The association between chronic pain and obesity
Okifuji, A., & Hare, B. (2015) · Journal of Pain Research · doi:10.2147/jpr.s55598 · Cited by 597
Metadata
- Authors
- Tzellos, T. G., Toulis, K. A., Goulis, D. G., Papazisis, G., Zampeli, V. A., Vakfari, A., & Kouvelas, D.
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Wiley
- Published
- 2010-11-03
- Volume
- 35
- Issue
- 6
- Pages
- 639-656
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W1960053172
- Cited by
- 108
- References
- 12
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis: Gabapentin and pregabalin in treating fibromyalgia. https://app.cochat.ai/papers/10.1111/j.1365-2710.2009.01144.x
- The paper
- Tzellos, T. G., Toulis, K. A., Goulis, D. G., Papazisis, G., Zampeli, V. A., Vakfari, A., & Kouvelas, D. (2010). Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis: Gabapentin and pregabalin in treating fibromyalgia. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/j.1365-2710.2009.01144.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.